Close Menu

NEW YORK (GenomeWeb) – AstraZeneca will use Bina Technologies' genome analysis software as an enterprise platform to support its development work across three therapeutic areas, the companies said today.

Under the collaboration agreement, the pharma company will adopt the Bina Genomic Management Solution (GMS) globally to support genomic data analysis and management as part of its development of drugs in oncology, cardiovascular and metabolic disease, respiratory disease, inflammation, and autoimmunity. AstraZeneca will also become the first member of the Bina Alliance Program.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.